The agriculture, animal health, and food industries share the same issues, but without established models in place and pools of available capital for shared de-risking.
The TechAccel science advancement model emerged from the Kansas State University Institute for Commercialization’s (KSU-IC) engagement with global Animal Health companies.
Those discussions identified a clear gap between technology concept and strong supporting evidence that a technology will work for its intended purpose - often referred to as “proof-of-concept."
Even if an early-stage technology has extensive market potential, the lack of supporting evidence nearly always leads companies to focus their limited resources on technologies with a lower risk profile, which in many instances have less market opportunity.
Recognizing this development gap and the opportunity related to shifting global demographics, led to the formation of TechAccel with Michael Helmstetter, Ph.D.
During its formative phase, TechAccel rapidly expanded to include agriculture and food industry sectors.
TechAccel is further advancing the model, leveraging many of the concepts and funding strategies used in the human health industry.
In the human health industry, private capital is deployed to share the financial risk of early-stage pharmaceutical development. This lower risk-profile then can attract a larger co-development partner.
They are then applied in novel ways to co-develop transformative technologies in partnership with multinational and emerging agriculture, animal health, and food companies, as well as venture capital firms.
TechAccel is the first private capital co-development science partner serving these sectors.
Through collaborations with universities and research organizations, TechAccel conducts innovative research and development to ready technologies for commercialization by TechAccel's global industry partners.